Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 17 Gastrointestinal 8 Thoracic 4 Sarcoma 3 Plasma cell 3 Lymphoid 2 Gynecologic 2 Genitourinary 2 CNS 2 Tumor-Agnostic 1 Other neoplasm 1 Other hematologic neoplasm 1 Other 1 Myeloid 1 Dermatologic 1 Breast 1

Conditions

Venous Thromboembolism 1 Obesity 1 Neoplasms 1

Interventions

Exercise 28 Metformin 24 Surveys and Questionnaires 19 Radiotherapy 14 Methods 14 Early Intervention, Educational 13 Counseling 13 Educational Status 12 naloxegol 10 Standard of Care 10 Tirzepatide 9 Nutrition Assessment 9 Diet Therapy 9 Cisplatin 9 Resistance Training 8 Psychiatric Rehabilitation 8 Diet 8 Therapeutics 7 Interviews as Topic 7 alvimopan 6 Liraglutide 6 Fibroblast Growth Factor 7 6 Caloric Restriction 6 semaglutide 5 Radiation 5 Low-Level Light Therapy 5 Injections 5 Exenatide 5 Diet, Mediterranean 5 Dexamethasone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Dalteparin × Other × Clear all

NCT03297359 2024-01-23

WAVe

Ottawa Hospital Research Institute

Phase 2 Terminated

Classical hematologyOther

Neoplasms, Obesity, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡